Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Acquires Proxeon

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today announced that it has acquired proteomics tools firm Proxeon for an undisclosed sum.

The privately-held Danish firm makes nanoflow liquid chromatography systems, columns, ion sources, and bioinformatics software for liquid chromatography/mass spectrometry analysis in complex proteomics applications. Proxeon's primary product is its Easy-nLC nanoflow liquid chromatography system.

"By offering a high-performance solution that addresses the need for simplified operation, we can meet the increasing demand for LC/MS in proteomics applications," Thermo Fisher President and CEO Marc Casper said in a statement. "These systems can be easily integrated with our leading ion trap, hybrid and triple quadrupole mass spectrometry systems, in line with our strategy of providing comprehensive LC/MS solutions for both high-end research and routine applications."

Proxeon had 2009 revenues of around $10 million, according to Thermo Fisher. The firm, which employs approximately 40 people, will be integrated into Thermo Fisher's Analytical Technologies Segment.

Thermo Fisher said that it does not expect the purchase to have a material impact on its 2010 financial results.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.